Treatment of HELLP Syndrome: Seizures Refractory to Magnesium Sulfate

In HELLP syndrome, seizures that persist despite initial anticonvulsant therapy represent a critical escalation point. A structured protocol governs how to proceed when standard first-line management is no longer sufficient.

Clinical scenario

Persistent or recurrent seizures in the setting of HELLP syndrome that have not resolved with magnesium sulfate, requiring escalation to alternative anticonvulsant management under intensive care conditions.

Treatment approach

When seizures in HELLP syndrome are refractory to magnesium sulfate, the protocol calls for specific anticonvulsant agents alongside intensive care monitoring and airway management — the full decision algorithm and regimen are available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/AOG.0000000000003891

In cases refractory to magnesium sulfate (still seizing at 20 minutes after the bolus or more than two recurrences), a health care provider can use sodium amobarbital (250 mg IV in 3 minutes), thiopental, or phenytoin (1,250 mg IV at a rate of 50 mg/minute).
Endotracheal intubation and assisted ventilation in the intensive care unit are appropriate in these circumstances.

View source ↗